Analog chipmaker Texas Instruments forecasts third-quarter revenue above estimates
The company expects revenue in the range of $4.45 billion to $4.80 billion for the third quarter, compared with analysts' average estimate of $4.59 billion, according to data compiled by LSEG.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
Health insurer Centene reports surprise quarterly loss
July 25 (Reuters) - Centene (CNC.N), opens new tab on Friday reported a surprise quarterly loss after the health insurer warned of a revenue slump from government-backed plans, sending its shares down nearly 3% in premarket trading. "We are disappointed by our second-quarter results, but we have a clear understanding of the trends that have impacted our performance, and are working with urgency and focus to restore our earnings trajectory," CEO Sarah London said. The health insurance industry has seen elevated medical costs and changing enrollment patterns, at a time when it braces for big spending cuts and rule changes under the Trump administration. Earlier this month, Centene withdrew its 2025 earnings forecast due to an expected revenue slump from commercial plans under Affordable Care Act, also known as Obamacare. These plans offer a sliding scale of government subsidies based on income. For the second quarter, the health insurer reported adjusted loss per share of 16 cents, compared to analysts estimates of a profit of 86 cents per share, according to data compiled by LSEG.
Reuters
4 hours ago
- Reuters
Indian drugmaker Cipla beats first-quarter profit view on higher domestic demand
July 25 (Reuters) - Cipla ( opens new tab, India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs. The company's consolidated net profit rose 10% to 12.98 billion rupees ($150 million) in the April-June quarter, beating analysts' average estimate of 12.11 billion rupees, per data compiled by LSEG. Total revenue increased 4% to 69.57 billion rupees, slightly below expectations of 70.64 billion rupees. Cipla's shares jumped 3.4% after the results and were set for their best day in nearly three months. The stock was the top gainer on the blue-chip Nifty 50 index (.NSEI), opens new tab. Revenue from India, Cipla's biggest market by sales, climbed 6% to 30.70 billion rupees, while North America revenue fell 7% to 19.33 billion rupees. The two regions account for three-fourths of the company's total sales. Cipla said growth in India was led by demand for drugs in therapy areas such as respiratory, urology and anti-infectives. However, delayed approvals for new drug applications and pricing pressure have weighed on the drugmaker's growth in the U.S. Drug prices in the U.S. are expected to drop as shortages ease and competition from new drugmakers intensifies, Macquarie analysts said in a pre-earnings note. Earlier this week, rival Dr Reddy's ( opens new tab missed quarterly profit estimates and flagged increased price erosion in certain key products, including lenalidomide in North America. ($1 = 86.5750 Indian rupees)
Reuters
4 hours ago
- Reuters
Indian drugmaker Cipla beats first-quarter profit view
July 25 (Reuters) - Cipla ( opens new tab, India's No. 3 drugmaker by sales, reported a first-quarter profit that beat market expectations on Friday. The company's consolidated net profit increased 10% to 12.98 billion rupees ($150 million) in the April-June quarter, beating analysts' estimates of 12.11 billion rupees, per data compiled by LSEG. ($1 = 86.5750 Indian rupees)
